An Open-Label, Single Dose, Pharmacokinetic Study of AL-60371 Otic Suspension, 0.3% in Pediatric Subjects Following Tympanostomy Tube Surgery

Trial Profile

An Open-Label, Single Dose, Pharmacokinetic Study of AL-60371 Otic Suspension, 0.3% in Pediatric Subjects Following Tympanostomy Tube Surgery

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2014

At a glance

  • Drugs Finafloxacin (Primary)
  • Indications Bacterial infections; Postoperative infections
  • Focus Pharmacokinetics
  • Sponsors Alcon
  • Most Recent Events

    • 12 Oct 2014 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Sep 2014 Planned End Date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 17 Sep 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top